The Role of Eosinophilic Cationic Protein in Inflammatory Bowel Disease

Introduction Eosinophils contribute to inflammatory bowel disease (IBD) pathogenesis by infiltrating the intestinal mucosa and releasing pro-inflammatory mediators, including eosinophilic cationic protein (ECP). Although biomarkers like C-reactive protein and fecal calprotectin commonly assess IBD activity, the clinical utility of eosinophil-derived markers like ECP is unclear. Our aims were to compare serum ECP across ulcerative colitis (UC), Crohn’s disease, and healthy controls, with the prespecified primary contrast UC vs. controls. Our secondary objectives were to examine associations between ECP and disease activity (CDAI, MAYO scores) and quality of life, and explanatory objectives were to assess correlations with white blood cells and neutrophil and eosinophil counts and explore UC-control discrimination. Methods We conducted an observational study including 50 IBD patients (20 Crohn’s disease patients, 30 UC patients) and 32 healthy controls. Clinical data recorded included disease duration, Crohn’s Disease Activity Index (CDAI), Mayo score for UC, and quality of life (IBDQ questionnaire). Serum ECP (enzyme immunoassay), eosinophil counts, and routine blood tests were measured. Statistical analysis employed Kruskal-Wallis with Dunn’s post-hoc tests, Mann-Whitney U tests, and Spearman’s correlation. Ethical approval and informed consent were obtained. Results Median serum ECP differed significantly among controls, Crohn’s, and UC patients (16,807 (13,007-24,314) pg/mL vs 18,496 (12,261-28,231) vs 24,224 (17,335-32,997); p=0.03). UC patients had significantly higher ECP than controls (p=0.008), while the increase in Crohn’s disease was not significant (p=0.418). ECP was higher in UC compared to Crohn’s disease, though this difference did not reach statistical significance (p=0.128). No significant differences emerged between Crohn’s disease and UC in total leukocyte count, eosinophil count, disease duration, or Inflammatory Bowel Disease Questionnaire (IBDQ) scores (all p>0.1). Serum ECP positively correlated with total leukocyte (r=0.279, p=0.049) and neutrophil counts (r=0.298, p=0.036) across IBD patients. No significant correlations existed between ECP and patient age, disease duration, CDAI, Mayo score, IBDQ, or eosinophil count (all p>0.1). Conclusion In this cross-sectional cohort, serum ECP was higher in UC vs controls and showed only modest associations with leukocytosis, while not tracking CDAI, partial Mayo, or IBDQ. These findings are hypothesis-generating and consistent with eosinophil involvement; they do not demonstrate mechanism or clinical utility and require prospective validation.

• Publication year

  2025

• Venue

  Cureus

• Publication date

  2025-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.7759/cureus.93934PMID 41200586PMCID 12588261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review

  2024cited by this paper
• Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?

  2021influential reference
• Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation

  2020cited by this paper
• Histopathologic Parameters at Diagnosis as Early Predictors of Histologic Remission along the Course of Ulcerative Colitis

  2020cited by this paper
• Genetic and shared environmental risk factors do not lead to eosinophil activation in healthy twins of IBD patients

  2020cited by this paper
• Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease

  2019influential reference
• ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications.

  2018cited by this paper
• Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and serum tumor necrosis factor α in patients with ulcerative colitis

  2015cited by this paper
• Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy

  2014cited by this paper
• Clinical value of serum eosinophilic cationic protein assessment in children with inflammatory bowel disease

  2013influential reference
• Recurrent Blood Eosinophilia in Ulcerative Colitis Is Associated with Severe Disease and Primary Sclerosing Cholangitis

  2012cited by this paper
• Role of Eosinophils in Inflammatory Bowel and Gastrointestinal Diseases

  2011cited by this paper
• Antibody to eosinophil cationic protein suppresses dextran sulfate sodium-induced colitis in rats.

  2005cited by this paper
• Immunohistochemical Study of Intestinal Eosinophils in Inflammatory Bowel Disease

  2003cited by this paper
• Serum Eosinophil Cationic Protein in Active and Quiescent Ulcerative Colitis

  2000cited by this paper
• Increased concentrations of eosinophilic cationic protein in whole-gut lavage fluid from children with inflammatory bowel disease.

  1999cited by this paper
• Serum eosinophil cationic protein in active and quiescent ulcerative colitis.

  1998cited by this paper
• A new measure of health status for clinical trials in inflammatory bowel disease.

  1989cited by this paper

• Carrier-free supramolecular architectonics of quercetin-berberine for safety-redefined therapy of ulcerative colitis.

  2026cites this paper